Reply to Shanthikumar et al.: Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: Do the Benefits Outweigh the Harms?

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1349-1350. doi: 10.1164/rccm.201808-1462LE.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents
  • Azithromycin
  • Cystic Fibrosis*
  • Humans
  • Pseudomonas Infections*
  • Pseudomonas aeruginosa

Substances

  • Anti-Bacterial Agents
  • Azithromycin